http://ift.tt/hZ0OVi
Craig Venter’s new company wants to improve human longevity by creating the world’s largest, most comprehensive database of genetic and physiological information.
Human Longevity Inc. (HLI) is a genomics and cell therapy-based diagnostic and therapeutic company. HLI will use advances in genomic sequencing, understanding the human microbiome, proteomics, informatics, computing, and cell therapy technologies to make progress to radical life extension. HLI is concentrating on cancer, diabetes and obesity, heart and liver diseases, and dementia.
Human Longevity, based in San Diego, says it will sequence some 40,000 human genomes per year to start, using Illumina’s new high-throughput sequencing machines at a cost of about $1000 per genome.
Eventually, it plans to work its way up to 100,000 genomes per year. The company will also sequence the genomes of the body’s multitudes of microbial inhabitants, called the microbiome, and analyze the thousands of metabolites that can be found in blood and other patient samples.
By combining these disparate types of data, the new company hopes to make inroads into the enigmatic process of aging and the many diseases, including cancer and heart disease, that are strongly associated with it. “Aging is exerting a force on humans that is exposing us to diseases, and the diseases are idiosyncratic, partly based on genetics, partly on environment,” says Leonard Guarente, who researches aging at MIT and is not involved in the company. “The hope for many of us who study aging is that by having interventions that hit key pathways in aging, we can affect disease.”
Human Microbiome - There are 100 times more cells from bacteria, fungi, and viruses, in and on your body than there are human cells. The metabolome includes the complete set of metabolites in a human genome.
Read more »
Reposted via Next Big Future
Craig Venter’s new company wants to improve human longevity by creating the world’s largest, most comprehensive database of genetic and physiological information.
Human Longevity Inc. (HLI) is a genomics and cell therapy-based diagnostic and therapeutic company. HLI will use advances in genomic sequencing, understanding the human microbiome, proteomics, informatics, computing, and cell therapy technologies to make progress to radical life extension. HLI is concentrating on cancer, diabetes and obesity, heart and liver diseases, and dementia.
Human Longevity, based in San Diego, says it will sequence some 40,000 human genomes per year to start, using Illumina’s new high-throughput sequencing machines at a cost of about $1000 per genome.
Eventually, it plans to work its way up to 100,000 genomes per year. The company will also sequence the genomes of the body’s multitudes of microbial inhabitants, called the microbiome, and analyze the thousands of metabolites that can be found in blood and other patient samples.
By combining these disparate types of data, the new company hopes to make inroads into the enigmatic process of aging and the many diseases, including cancer and heart disease, that are strongly associated with it. “Aging is exerting a force on humans that is exposing us to diseases, and the diseases are idiosyncratic, partly based on genetics, partly on environment,” says Leonard Guarente, who researches aging at MIT and is not involved in the company. “The hope for many of us who study aging is that by having interventions that hit key pathways in aging, we can affect disease.”
Human Microbiome - There are 100 times more cells from bacteria, fungi, and viruses, in and on your body than there are human cells. The metabolome includes the complete set of metabolites in a human genome.
Read more »
Reposted via Next Big Future
No comments:
Post a Comment